Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study

Behavioral and Brain Functions

Subin Park²  Ki Kyoung Yi¹  Min-Seon Kim³  Jin Pyo Hong¹ 

[1] Department of Psychiatry, Asan Medical Center, Ulsan University College of Medicine, Seoul, South Korea

[2] Division of Child and Adolescent Psychiatry, Department of Psychiatry, Seoul National University Hospital, Seoul, South Korea

[3] Department of Internal Medicine, Asan Medical Center, Ulsan University College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul, 138-736, South Korea

关键词: Body composition;    Resting energy expenditure;    Weight gain;    Olanzapine;    Ziprasidone;   

Others  :  793379
DOI  :  10.1186/1744-9081-9-27

 received in 2013-01-21, accepted in 2013-06-28,  发布年份 2013

【 摘 要 】

Background

In contrast to olanzapine, ziprasidone has been reported to cause minimal or no weight gain. This study aimed to compare the effects of ziprasidone and olanzapine on weight, body composition, appetite, resting energy expenditure, substrate oxidation, and metabolic parameters in adults with schizophrenia or other psychotic disorders.

Methods

Twenty adults with schizophrenia or other psychotic disorders were randomized 1:1 to ziprasidone 20–160 mg/day or olanzapine 5–20 mg/day for 12 weeks. The mean doses during the 12-week study period were 109(range: 65–140) mg/day for ziprasidone and 11.6(range: 8.2–15.5) mg/day for olanzapine. Body weight, appetite, body composition, resting energy expenditure, and metabolic parameters were measured before and after drug treatment. Outcome measurements before and after medication were compared, and ziprasidone- and olanzapine-treated patients were compared.

Results

After 12 weeks, olanzapine-treated patients showed significant weight gain, particularly fat gain, with increased low density lipoprotein-cholesterol and decreased high density lipoprotein-cholesterol concentrations. In contrast, ziprasidone-treated patients showed no significant weight gain with increased high density lipoprotein-cholesterol concentration.

Conclusions

Ziprasidone was associated with a lower propensity for weight gain and central fat deposition than olanzapine. Studies in larger patient samples are required to confirm these results.

【 授权许可】

   
2013 Park et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Allison DB, Casey DE: Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001, 62(Suppl 7):22-31.
• [2]Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
• [3]Lee E, Chow LY, Leung CM: Metabolic profile of first and second generation antipsychotics among Chinese patients. Psychiatry Res 2011, 185:456-458.
• [4]Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R: Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002, 41:337-343.
• [5]Saddichha S, Ameen S, Akhtar S: Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients. Schizophr Res 2007, 95:247.
• [6]Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997, 154:457-465.
• [7]Almeras N, Despres JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, Mottard JP, Bouchard RH: Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004, 65:557-564.
• [8]Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R: Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998, 59:294-299.
• [9]Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O: Glucose intolerance with atypical antipsychotics. Drug Saf 2002, 25:1107-1116.
• [10]Jin H, Meyer JM, Jeste DV: Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004, 71:195-212.
• [11]Melkersson K, Dahl ML: Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004, 64:701-723.
• [12]Arato M, O'Connor R, Meltzer HY: A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002, 17:207-215.
• [13]Daniel DG: Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry 2003, 64(Suppl 19):40-49.
• [14]Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM: The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001, 62:347-349.
• [15]Kudla D, Lambert M, Domin S, Kasper S, Naber D: Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. Eur Psychiatry 2007, 22:195-202.
• [16]Manschreck TC, Boshes RA: The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 2007, 15:245-258.
• [17]Ratner Y, Gibel A, Yorkov V, Ritsner MS: Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1401-1409.
• [18]Brown RR, Estoup MW: Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 2005, 20:105-112.
• [19]Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS: Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol 2010, 33:121-125.
• [20]Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S: Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009, CD006627.
• [21]Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L: Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004, 5:279-299.
• [22]Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, Cheetham S, Neill JC: The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl) 2007, 194:221-231.
• [23]Shobo M, Yamada H, Mihara T, Kondo Y, Irie M, Harada K, Ni K, Matsuoka N, Kayama Y: Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Behav Brain Res 2011, 216:561-568.
• [24]von Wilmsdorff M, Bouvier ML, Henning U, Schmitt A, Gaebel W: The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. Clinics (Sao Paulo) 2010, 65:885-894.
• [25]Park S, Kim MS, Namkoong C, Park MH, Hong JP: The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism 2012, 61:787-793.
• [26]Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, et al.: Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002, 159:1055-1057.
• [27]Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB: Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005, 162:118-123.
• [28]Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL: A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007, 68:1733-1740.
• [29]Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA: Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring) 2010, 18:1646-1651.
• [30]Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A: Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. Pharmacopsychiatry 2002, 35:124-126.
• [31]Hahn OS, Ahn JH, Song SH, Cho MJ, Kim JK, Bae JN: Development of Korean version of structured clinical interview schedule for DSM-IV axis I disorder : interrater reliability. Journal of the Korean Neuropsychiatric Association 2000, 39:362-372.
• [32]Yi J-S, Ahn YM, Shin H-K, An SK, Joo Y-H, Kim S-H, Yoon DJ, Jho K-H, Koo Y-J, Lee JY, et al.: Reliability and validity of the Korean version of the positive and negative syndrome scale. Korean Neuropsychiatric Association 2002, 40:1090-1105.
• [33]Hill AJ, Magson LD, Blundell JE: Hunger and palatability: tracking ratings of subjective experience before, during and after the consumption of preferred and less preferred food. Appetite 1984, 5:361-371.
• [34]Weinsier RL, Nelson KM, Hensrud DD, Darnell BE, Hunter GR, Schutz Y: Metabolic predictors of obesity. Contribution of resting energy expenditure, thermic effect of food, and fuel utilization to four-year weight gain of post-obese and never-obese women. J Clin Invest 1995, 95:980-985.
• [35]Coccurello R, Brina D, Caprioli A, Conti R, Ghirardi O, Schepis F, Moles A: 30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice. J Clin Psychopharmacol 2009, 29:576-583.
• [36]Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, Daniele S, Bartolomucci A, Moles A: Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) 2006, 186:561-571.
• [37]Liebig M, Gossel M, Pratt J, Black M, Haschke G, Elvert R, Juretschke HP, Neumann-Haefelin C, Kramer W, Herling AW: Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring) 2010, 18:1952-1958.
• [38]Schutz Y: Abnormalities of fuel utilization as predisposing to the development of obesity in humans. Obes Res 1995, 3(Suppl 2):173S-178S.